Krystal Biotech (NASDAQ:KRYS) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Krystal Biotech (NASDAQ:KRYS) issued its earnings results on Monday. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07, Briefing.com reports. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s revenue was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.67) EPS.

Krystal Biotech Trading Down 3.1 %

Shares of NASDAQ:KRYS opened at $170.85 on Tuesday. The company has a market cap of $4.91 billion, a price-to-earnings ratio of 46.81 and a beta of 0.82. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The company has a 50-day moving average price of $182.28 and a 200 day moving average price of $180.12.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KRYS shares. Citigroup restated a “neutral” rating and set a $204.00 price objective (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus raised their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, HC Wainwright lifted their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $196.75.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).